{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T16:39:29Z","timestamp":1791218369474,"version":"4.1.0"},"reference-count":87,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100001245","name":"Jeffrey Modell Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001245","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["annallergy.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annals of Allergy, Asthma & Immunology"],"published-print":{"date-parts":[[2022,11]]},"DOI":"10.1016\/j.anai.2022.06.009","type":"journal-article","created":{"date-parts":[[2022,6,16]],"date-time":"2022-06-16T02:25:17Z","timestamp":1655346317000},"page":"562-571.e1","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":27,"title":["Immunizing the imperfect immune system"],"prefix":"10.1016","volume":"129","author":[{"given":"Jessica R.","family":"Durkee-Shock","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael D.","family":"Keller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.anai.2022.06.009_bib0001","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1158\/2159-8290.CD-20-0422","article-title":"Patients with cancer appear more vulnerable to SARS-CoV-2: a multicenter study during the COVID-19 outbreak","volume":"10","author":"Dai","year":"2020","journal-title":"Cancer Discov"},{"issue":"3","key":"10.1016\/j.anai.2022.06.009_bib0002","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/S1470-2045(20)30096-6","article-title":"Cancer patients in SARS-CoV-2 infection: a nationwide analysis in China","volume":"21","author":"Liang","year":"2020","journal-title":"Lancet Oncol"},{"issue":"2","key":"10.1016\/j.anai.2022.06.009_bib0003","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1016\/j.jaci.2020.09.010","article-title":"Coronavirus disease 2019 in patients with inborn errors of immunity: an international study","volume":"147","author":"Meyts","year":"2021","journal-title":"J Allergy Clin Immunol"},{"issue":"2","key":"10.1016\/j.anai.2022.06.009_bib0004","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1016\/j.jaci.2020.09.020","article-title":"Severe SARS-CoV-2 disease in the context of a NF-\u03baB2 loss-of-function pathogenic variant","volume":"147","author":"Abraham","year":"2021","journal-title":"J Allergy Clin Immunol"},{"issue":"1","key":"10.1016\/j.anai.2022.06.009_bib0005","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1016\/j.jaip.2020.09.052","article-title":"Clinical outcomes and features of COVID-19 in patients with primary immunodeficiencies in New York City","volume":"9","author":"Ho","year":"2021","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"1","key":"10.1016\/j.anai.2022.06.009_bib0006","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1111\/all.15025","article-title":"Adverse COVID-19 outcomes in immune deficiencies: inequality exists between subclasses","volume":"77","author":"Karakoc Aydiner","year":"2022","journal-title":"Allergy"},{"issue":"1","key":"10.1016\/j.anai.2022.06.009_bib0007","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/j.jaci.2020.04.013","article-title":"A possible role for B cells in COVID-19? Lesson from patients with agammaglobulinemia","volume":"146","author":"Quinti","year":"2020","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.anai.2022.06.009_bib0008","doi-asserted-by":"crossref","unstructured":"Sowers KL, Galantino ML. Living with primary immunodeficiency disease during the Covid-19 pandemic [e-pub ahead of print]. Z Gesundh Wiss. 2021. doi:10.1007\/s10389-021-01545-7, accessed July 06, 2022.","DOI":"10.1007\/s10389-021-01545-7"},{"issue":"6515","key":"10.1016\/j.anai.2022.06.009_bib0009","doi-asserted-by":"crossref","first-page":"eabd4585","DOI":"10.1126\/science.abd4585","article-title":"Autoantibodies against type I IFNs in patients with life-threatening COVID-19","volume":"370","author":"Bastard","year":"2020","journal-title":"Science"},{"issue":"7","key":"10.1016\/j.anai.2022.06.009_bib0010","doi-asserted-by":"crossref","DOI":"10.1084\/jem.20210554","article-title":"Preexisting autoantibodies to type I IFNs underlie critical COVID-19 pneumonia in patients with APS-1","volume":"218","author":"Bastard","year":"2021","journal-title":"J Exp Med"},{"issue":"6","key":"10.1016\/j.anai.2022.06.009_bib0011","doi-asserted-by":"crossref","first-page":"1894","DOI":"10.1016\/j.jaip.2020.04.003","article-title":"Health-related quality of life in common variable immunodeficiency Italian patients switched to remote assistance during the COVID-19 pandemic","volume":"8","author":"Pulvirenti","year":"2020","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"1","key":"10.1016\/j.anai.2022.06.009_bib0012","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1089\/ped.2021.0081","article-title":"Psychological state of parents of children with primary immunodeficiencies during the COVID-19 pandemic","volume":"35","author":"Akda\u011f","year":"2022","journal-title":"Pediatr Allergy Immunol Pulmonol"},{"issue":"6","key":"10.1016\/j.anai.2022.06.009_bib0013","doi-asserted-by":"crossref","first-page":"1146","DOI":"10.1007\/s10875-021-01046-y","article-title":"Robust antibody and T cell responses to SARS-CoV-2 in patients with antibody deficiency","volume":"41","author":"Kinoshita","year":"2021","journal-title":"J Clin Immunol"},{"issue":"21","key":"10.1016\/j.anai.2022.06.009_bib0014","doi-asserted-by":"crossref","first-page":"2417","DOI":"10.1016\/j.vaccine.2016.03.091","article-title":"Cellular and humoral influenza-specific immune response upon vaccination in patients with common variable immunodeficiency and unclassified antibody deficiency","volume":"34","author":"Hanitsch","year":"2016","journal-title":"Vaccine"},{"issue":"6","key":"10.1016\/j.anai.2022.06.009_bib0015","doi-asserted-by":"crossref","first-page":"e1397","DOI":"10.1093\/cid\/ciab397","article-title":"Improving the outcomes of immunocompromised patients with coronavirus disease 2019","volume":"73","author":"Haidar","year":"2021","journal-title":"Clin Infect Dis"},{"issue":"6536","key":"10.1016\/j.anai.2022.06.009_bib0016","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.1126\/science.abg4493","article-title":"The emerging plasticity of SARS-CoV-2","volume":"371","author":"McCormick","year":"2021","journal-title":"Science"},{"issue":"7853","key":"10.1016\/j.anai.2022.06.009_bib0017","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1038\/s41586-021-03291-y","article-title":"SARS-CoV-2 evolution during treatment of chronic infection","volume":"592","author":"Kemp","year":"2021","journal-title":"Nature"},{"issue":"9","key":"10.1016\/j.anai.2022.06.009_bib0018","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1056\/NEJMoa2117608","article-title":"Final analysis of efficacy and safety of single-dose Ad26.COV2.S","volume":"386","author":"Sadoff","year":"2022","journal-title":"N Engl J Med"},{"issue":"19","key":"10.1016\/j.anai.2022.06.009_bib0019","doi-asserted-by":"crossref","first-page":"1774","DOI":"10.1056\/NEJMoa2113017","article-title":"Efficacy of the mRNA-1273 SARS-CoV-2 vaccine at completion of blinded phase","volume":"385","author":"El Sahly","year":"2021","journal-title":"N Engl J Med"},{"issue":"27","key":"10.1016\/j.anai.2022.06.009_bib0020","doi-asserted-by":"crossref","first-page":"2603","DOI":"10.1056\/NEJMoa2034577","article-title":"Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine","volume":"383","author":"Polack","year":"2020","journal-title":"N Engl J Med"},{"issue":"25","key":"10.1016\/j.anai.2022.06.009_bib0022","doi-asserted-by":"crossref","first-page":"2439","DOI":"10.1056\/NEJMoa2027906","article-title":"Safety and immunogenicity of two RNA-based Covid-19 vaccine candidates","volume":"383","author":"Walsh","year":"2020","journal-title":"N Engl J Med"},{"issue":"19","key":"10.1016\/j.anai.2022.06.009_bib0023","doi-asserted-by":"crossref","first-page":"1824","DOI":"10.1056\/NEJMoa2034201","article-title":"Interim Results of a phase 1-2a trial of Ad26.COV2.S Covid-19 vaccine","volume":"384","author":"Sadoff","year":"2021","journal-title":"N Engl J Med"},{"issue":"20","key":"10.1016\/j.anai.2022.06.009_bib0024","doi-asserted-by":"crossref","first-page":"1920","DOI":"10.1056\/NEJMoa2022483","article-title":"An mRNA vaccine against SARS-CoV-2 - preliminary report","volume":"383","author":"Jackson","year":"2020","journal-title":"N Engl J Med"},{"issue":"21","key":"10.1016\/j.anai.2022.06.009_bib0025","doi-asserted-by":"crossref","first-page":"2010","DOI":"10.1056\/NEJMc2115596","article-title":"Differential kinetics of immune responses elicited by Covid-19 vaccines","volume":"385","author":"Collier","year":"2021","journal-title":"N Engl J Med"},{"issue":"17","key":"10.1016\/j.anai.2022.06.009_bib0026","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1056\/NEJMc2113468","article-title":"SARS-CoV-2 neutralization with BNT162b2 vaccine dose 3","volume":"385","author":"Falsey","year":"2021","journal-title":"N Engl J Med"},{"issue":"6561","key":"10.1016\/j.anai.2022.06.009_bib0027","doi-asserted-by":"crossref","first-page":"1372","DOI":"10.1126\/science.abj4176","article-title":"Durability of mRNA-1273 vaccine-induced antibodies against SARS-CoV-2 variants","volume":"373","author":"Pegu","year":"2021","journal-title":"Science"},{"key":"10.1016\/j.anai.2022.06.009_bib0028","unstructured":"Interim Clinical Considerations for Use of COVID-19 Vaccines Currently Approved or Authorized in the United States; 2022.https:\/\/www.cdc.gov\/vaccines\/covid-19\/clinical-considerations\/covid-19-vaccines-us.html. Accessed July 6, 2022."},{"issue":"3","key":"10.1016\/j.anai.2022.06.009_bib0029","doi-asserted-by":"crossref","DOI":"10.1016\/j.cell.2021.12.032","article-title":"The Omicron variant is highly resistant against antibody-mediated neutralization: implications for control of the COVID-19 pandemic","volume":"185","author":"Hoffmann","year":"2022","journal-title":"Cell"},{"key":"10.1016\/j.anai.2022.06.009_bib0030","doi-asserted-by":"crossref","unstructured":"Lu L, Mok BW, Chen LL, Chan JMC, Tsang OTY, Lam BHS, et al. Neutralization of SARS-CoV-2 Omicron variant by sera from BNT162b2 or Coronavac vaccine recipients [e-pub ahead of print]. Clin Infect Dis. 2021. doi:10.1093\/cid\/ciab1041, Accessed July 6, 2022.","DOI":"10.1093\/cid\/ciab1041"},{"key":"10.1016\/j.anai.2022.06.009_bib0031","article-title":"Vaccines elicit highly cross-reactive cellular immunity to the SARS-CoV-2 omicron variant","author":"Liu","year":"2022","journal-title":"medRxiv"},{"issue":"7","key":"10.1016\/j.anai.2022.06.009_bib0032","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaip.2020.04.019","article-title":"Preserved cellular immunity upon influenza vaccination in most patients with common variable immunodeficiency","volume":"8","author":"Friedmann","year":"2020","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"3","key":"10.1016\/j.anai.2022.06.009_bib0033","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1007\/s10875-011-9639-y","article-title":"Dendritic and T cell response to influenza is normal in the patients with X-linked agammaglobulinemia","volume":"32","author":"Liu","year":"2012","journal-title":"J Clin Immunol"},{"issue":"4","key":"10.1016\/j.anai.2022.06.009_bib0034","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1016\/j.jaci.2013.11.043","article-title":"Recommendations for live viral and bacterial vaccines in immunodeficient patients and their close contacts","volume":"133","author":"Shearer","year":"2014","journal-title":"J Allergy Clin Immunol"},{"issue":"24","key":"10.1016\/j.anai.2022.06.009_bib0035","doi-asserted-by":"crossref","first-page":"3541","DOI":"10.1016\/j.vaccine.2018.01.061","article-title":"Vaccination in immunocompromised host: recommendations of Italian Primary Immunodeficiency Network Centers (IPINET) [published correction appears in Vaccine. 2018;36(50):7753]","volume":"36","author":"Martire","year":"2018","journal-title":"Vaccine"},{"issue":"5","key":"10.1016\/j.anai.2022.06.009_bib0036","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1016\/j.jaci.2021.08.016","article-title":"Antibody responses to the SARS-CoV-2 vaccine in individuals with various inborn errors of immunity","volume":"148","author":"Delmonte","year":"2021","journal-title":"J Allergy Clin Immunol"},{"issue":"2","key":"10.1016\/j.anai.2022.06.009_bib0037","article-title":"Salivary IgG to SARS-CoV-2 indicates seroconversion and correlates to serum neutralization in mRNA-vaccinated immunocompromised individuals","volume":"3","author":"Healy","year":"2022","journal-title":"Med (N Y)"},{"issue":"1","key":"10.1016\/j.anai.2022.06.009_bib0038","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.jaci.2021.08.031","article-title":"Impaired memory B-cell response to the Pfizer-BioNTech COVID-19 vaccine in patients with common variable immunodeficiency","volume":"149","author":"Fernandez Salinas","year":"2022","journal-title":"J Allergy Clin Immunol"},{"issue":"6","key":"10.1016\/j.anai.2022.06.009_bib0039","doi-asserted-by":"crossref","first-page":"1949","DOI":"10.1016\/j.jaci.2022.04.002","article-title":"Immunogenicity of the mRNA-1273 COVID-19 vaccine in adult patients with inborn errors of immunity","volume":"149","author":"van Leeuwen","year":"2022","journal-title":"J Allergy Clin Immunol"},{"issue":"4","key":"10.1016\/j.anai.2022.06.009_bib0044","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1016\/j.anai.2021.07.021","article-title":"Specific antibody response of patients with common variable immunodeficiency to BNT162b2 coronavirus disease 2019 vaccination","volume":"127","author":"Abo-Helo","year":"2021","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.anai.2022.06.009_bib0049","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.727850","article-title":"Humoral and cellular response following vaccination with the BNT162b2 mRNA COVID-19 vaccine in patients affected by primary immunodeficiencies","volume":"12","author":"Amodio","year":"2021","journal-title":"Front Immunol"},{"key":"10.1016\/j.anai.2022.06.009_bib0081","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.895209","article-title":"Evaluation of humoral and cellular immune responses to the SARS-CoV-2 vaccine in patients with common variable immunodeficiency phenotype and patient receiving B-cell depletion therapy","volume":"13","author":"Antoli","year":"2022","journal-title":"Front Immunol"},{"issue":"2","key":"10.1016\/j.anai.2022.06.009_bib0052","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1007\/s10875-021-01174-5","article-title":"Immunogenicity of anti-SARS-CoV-2 vaccines in common variable immunodeficiency","volume":"42","author":"Arroyo-S\u00e1nchez","year":"2022","journal-title":"J Clin Immunol"},{"issue":"6","key":"10.1016\/j.anai.2022.06.009_bib0041","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaip.2022.03.017","article-title":"Response to SARS-CoV-2 initial series and additional dose vaccine in patients with predominant antibody deficiency","volume":"10","author":"Barmettler","year":"2022","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"3","key":"10.1016\/j.anai.2022.06.009_bib0082","doi-asserted-by":"crossref","first-page":"101","DOI":"10.15586\/aei.v50i3.583","article-title":"Easy approach to detect cell immunity to COVID vaccines in common variable immunodeficiency patients","volume":"50","author":"Barrios","year":"2022","journal-title":"Allergol Immunopathol (Madr)"},{"key":"10.1016\/j.anai.2022.06.009_bib0067","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2021.103705","article-title":"Safety and efficacy of the mRNA BNT162b2 vaccine against SARS-CoV-2 in five groups of immunocompromised patients and healthy controls in a prospective open-label clinical trial","volume":"74","author":"Bergman","year":"2021","journal-title":"EBiomedicine"},{"issue":"1","key":"10.1016\/j.anai.2022.06.009_bib0057","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1007\/s10875-021-01158-5","article-title":"Immunodeficiency Centre for Wales. Persistent COVID-19 infection in Wiskott-Aldrich syndrome cleared following therapeutic vaccination: a case report","volume":"42","author":"Bradley","year":"2022","journal-title":"J Clin Immunol"},{"key":"10.1016\/j.anai.2022.06.009_bib0088","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.907125","article-title":"Specific antibody and the T-cell response elicited by BNT162b2 boosting after two ChAdOx1 nCoV-19 in common variable immunodeficiency","author":"Goda","year":"2022","journal-title":"Front Immunol"},{"key":"10.1016\/j.anai.2022.06.009_bib0055","doi-asserted-by":"crossref","unstructured":"Gupta S, Agrawal S, Sandoval A, Su H, Tran M, Demirdag Y. SARS-CoV-2-Specific and functional cytotoxic CD8 cells in primary antibody deficiency: natural infection and response to vaccine [e-pub ahead of print]. J Clin Immunol. 2022. doi:10.1007\/s10875-022-01256-y, Accessed July 6, 2022.","DOI":"10.1007\/s10875-022-01256-y"},{"issue":"3","key":"10.1016\/j.anai.2022.06.009_bib0054","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1016\/j.jaci.2021.05.029","article-title":"Immunogenicity of Pfizer-BioNTech COVID-19 vaccine in patients with inborn errors of immunity","volume":"148","author":"Hagin","year":"2021","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.anai.2022.06.009_bib0083","doi-asserted-by":"crossref","DOI":"10.1177\/21526567211049744","article-title":"The successful vaccination of an IVIgG naive CVID patient with an mRNA COVID-19 vaccine","volume":"12","author":"Jalil","year":"2021","journal-title":"Allergy Rhinol (Providence)"},{"key":"10.1016\/j.anai.2022.06.009_bib0084","doi-asserted-by":"crossref","DOI":"10.1177\/21526567211056239","article-title":"Successful anti-SARS-CoV-2 spike protein antibody response to vaccination in MAGT1 deficiency","volume":"12","author":"Jalil","year":"2021","journal-title":"Allergy Rhinol (Providence)"},{"key":"10.1016\/j.anai.2022.06.009_bib0080","doi-asserted-by":"crossref","DOI":"10.1016\/j.clinsp.2022.100007","article-title":"Patient with agammaglobulinemia produces anti-SARS-CoV-2 reactive T-cells after CoronaVac vaccine","volume":"77","author":"Oshiro","year":"2022","journal-title":"Clinics (Sao Paulo)"},{"issue":"3","key":"10.1016\/j.anai.2022.06.009_bib0051","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaci.2021.11.022","article-title":"Immunogenicity and tolerability of COVID-19 messenger RNA vaccines in primary immunodeficiency patients with functional B-cell defects","volume":"149","author":"Pham","year":"2022","journal-title":"J Allergy Clin Immunol"},{"issue":"4","key":"10.1016\/j.anai.2022.06.009_bib0040","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1007\/s10875-022-01223-7","article-title":"Immunodeficiency Centre for Wales and Division of Population Medicine. COVID-19 vaccine uptake and efficacy in a national immunodeficiency cohort","volume":"42","author":"Ponsford","year":"2022","journal-title":"J Clin Immunol"},{"issue":"11","key":"10.1016\/j.anai.2022.06.009_bib0046","doi-asserted-by":"crossref","first-page":"2915","DOI":"10.3390\/cells10112915","article-title":"B cell response induced by SARS-CoV-2 infection is boosted by the BNT162b2 vaccine in primary antibody deficiencies","volume":"10","author":"Pulvirenti","year":"2021","journal-title":"Cells"},{"issue":"4","key":"10.1016\/j.anai.2022.06.009_bib0085","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1016\/j.anai.2021.07.026","article-title":"Detection of neutralizing anti-severe acute respiratory syndrome coronavirus 2 antibodies in patients with common variable immunodeficiency after immunization with messenger RNA vaccines","volume":"127","author":"Romano","year":"2021","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"8","key":"10.1016\/j.anai.2022.06.009_bib0048","doi-asserted-by":"crossref","first-page":"1709","DOI":"10.1007\/s10875-021-01133-0","article-title":"SARS-CoV-2 vaccine induced atypical immune responses in antibody defects: everybody does their best","volume":"41","author":"Salinas","year":"2021","journal-title":"J Clin Immunol"},{"key":"10.1016\/j.anai.2022.06.009_bib0086","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.827048","article-title":"Antigen-specific CD4(+) T-cell activation in primary antibody deficiency after BNT162b2 mRNA COVID-19 vaccination","volume":"13","author":"Sauerwein","year":"2022","journal-title":"Front Immunol"},{"issue":"9","key":"10.1016\/j.anai.2022.06.009_bib0078","doi-asserted-by":"crossref","first-page":"ofab420","DOI":"10.1093\/ofid\/ofab420","article-title":"Cross-reactive antibody response to mRNA SARS-CoV-2 vaccine after recent COVID-19-specific monoclonal antibody therapy","volume":"8","author":"Schultz-Cherry","year":"2021","journal-title":"Open Forum Infect Dis"},{"key":"10.1016\/j.anai.2022.06.009_bib0042","doi-asserted-by":"crossref","unstructured":"Shields AM, Faustini SE, Hill HJ, Al-Taei S, Tanner C, Ashford F, et al. SARS-CoV-2 vaccine responses in individuals with antibody deficiency: findings from the COV-AD study [e-pub ahead of print]. J Clin Immunol. 2022. doi:10.1007\/s10875-022-01231-7, Accessed July 6, 2022.","DOI":"10.1007\/s10875-022-01231-7"},{"issue":"3","key":"10.1016\/j.anai.2022.06.009_bib0073","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/j.anai.2021.05.015","article-title":"Seroconversion after coronavirus disease 2019 vaccination in patients with immune deficiency","volume":"127","author":"Squire","year":"2021","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"3","key":"10.1016\/j.anai.2022.06.009_bib0043","doi-asserted-by":"crossref","first-page":"e326","DOI":"10.1016\/S2214-109X(21)00593-3","article-title":"Response to additional COVID-19 vaccine doses in people who are immunocompromised: a rapid review","volume":"10","author":"Parker","year":"2022","journal-title":"Lancet Glob Health"},{"key":"10.1016\/j.anai.2022.06.009_bib0045","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.803742","article-title":"CD19+IgD+CD27- naive B cells as predictors of humoral response to COVID 19 mRNA vaccination in immunocompromised patients","volume":"12","author":"Schulz","year":"2021","journal-title":"Front Immunol"},{"key":"10.1016\/j.anai.2022.06.009_bib0047","article-title":"The immune response to SARS-CoV-2 vaccination: insights learned from adult patients with common variable immune deficiency","volume":"12","author":"Quinti","year":"2021","journal-title":"Front Immunol"},{"issue":"1","key":"10.1016\/j.anai.2022.06.009_bib0050","doi-asserted-by":"crossref","first-page":"2511","DOI":"10.1038\/s41467-020-16452-w","article-title":"A human monoclonal antibody blocking SARS-CoV-2 infection","volume":"11","author":"Wang","year":"2020","journal-title":"Nat Commun"},{"issue":"25","key":"10.1016\/j.anai.2022.06.009_bib0053","doi-asserted-by":"crossref","first-page":"2348","DOI":"10.1056\/NEJMoa2105290","article-title":"Phase 3 safety and efficacy of AZD1222 (ChAdOx1 nCoV-19) Covid-19 vaccine","volume":"385","author":"Falsey","year":"2021","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.anai.2022.06.009_bib0056","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1080\/13696998.2021.2002063","article-title":"Evaluation of COVID-19 vaccine breakthrough infections among immunocompromised patients fully vaccinated with BNT162b2","volume":"24","author":"Di Fusco","year":"2021","journal-title":"J Med Econ"},{"issue":"2","key":"10.1016\/j.anai.2022.06.009_bib0058","article-title":"COVID-19 and autoinflammatory diseases: prevalence and outcomes of infection and early experience of vaccination in patients on biologics","volume":"5","author":"Peet","year":"2021","journal-title":"Rheumatol Adv Pract"},{"issue":"11","key":"10.1016\/j.anai.2022.06.009_bib0059","doi-asserted-by":"crossref","first-page":"1925","DOI":"10.1007\/s00296-021-04972-7","article-title":"Local and systemic reactogenicity of COVID-19 vaccine BNT162b2 in patients with systemic lupus erythematosus and rheumatoid arthritis","volume":"41","author":"Bartels","year":"2021","journal-title":"Rheumatol Int"},{"issue":"5","key":"10.1016\/j.anai.2022.06.009_bib0060","doi-asserted-by":"crossref","DOI":"10.1053\/j.gastro.2021.06.076","article-title":"BNT162b2 messenger RNA COVID-19 vaccine effectiveness in patients with inflammatory bowel disease: preliminary real-world data during mass vaccination campaign","volume":"161","author":"Ben-Tov","year":"2021","journal-title":"Gastroenterology"},{"issue":"4","key":"10.1016\/j.anai.2022.06.009_bib0061","doi-asserted-by":"crossref","DOI":"10.1053\/j.gastro.2021.06.014","article-title":"COVID-19 vaccination is safe and effective in patients with inflammatory bowel disease: analysis of a Large Multi-institutional Research Network in The United States","volume":"161","author":"Hadi","year":"2021","journal-title":"Gastroenterology"},{"issue":"7","key":"10.1016\/j.anai.2022.06.009_bib0087","doi-asserted-by":"crossref","first-page":"1527","DOI":"10.1007\/s10875-021-01101-8","article-title":"Safety of COVID-19 vaccination in immune-deficient patients receiving supplemental immunoglobulin therapies","volume":"41","author":"Squire","year":"2021","journal-title":"J Clin Immunol"},{"issue":"4","key":"10.1016\/j.anai.2022.06.009_bib0062","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1001\/jama.2021.24110","article-title":"Myocarditis cases reported after mRNA-based COVID-19 vaccination in the US from December 2020 to August 2021","volume":"327","author":"Oster","year":"2022","journal-title":"JAMA"},{"issue":"7","key":"10.1016\/j.anai.2022.06.009_bib0063","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1038\/s41591-021-01408-4","article-title":"First-dose ChAdOx1 and BNT162b2 COVID-19 vaccines and thrombocytopenic, thromboembolic and hemorrhagic events in Scotland","volume":"27","author":"Simpson","year":"2021","journal-title":"Nat Med"},{"issue":"22","key":"10.1016\/j.anai.2022.06.009_bib0064","doi-asserted-by":"crossref","first-page":"2256","DOI":"10.1182\/blood.2021013231","article-title":"Insights in ChAdOx1 nCoV-19 vaccine-induced immune thrombotic thrombocytopenia","volume":"138","author":"Greinacher","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.anai.2022.06.009_bib0065","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.763412","article-title":"COVID-19 in B cell-depleted patients after rituximab: a diagnostic and therapeutic challenge","volume":"12","author":"Furlan","year":"2021","journal-title":"Front Immunol"},{"issue":"2","key":"10.1016\/j.anai.2022.06.009_bib0066","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1093\/jnci\/djab174","article-title":"Immunogenicity and safety of the BNT162b2 mRNA COVID-19 vaccine among actively treated cancer patients","volume":"114","author":"Ligumsky","year":"2022","journal-title":"J Natl Cancer Inst"},{"issue":"10","key":"10.1016\/j.anai.2022.06.009_bib0068","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.3390\/vaccines9101147","article-title":"Challenges to vaccination against SARS-CoV-2 in patients with immune-mediated diseases","volume":"9","author":"Ramirez","year":"2021","journal-title":"Vaccines (Basel)"},{"issue":"2","key":"10.1016\/j.anai.2022.06.009_bib0069","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1016\/S0022-3476(06)80114-9","article-title":"Interference of immune globulin with measles and rubella immunization","volume":"122","author":"Siber","year":"1993","journal-title":"J Pediatr"},{"key":"10.1016\/j.anai.2022.06.009_bib0070","doi-asserted-by":"crossref","unstructured":"Karbiener M, Farcet MR, Schwaiger J, Powers N, Lenart J, Stewart JM, et al. Plasma from post-COVID-19 and COVID-19-vaccinated donors results in highly potent SARS-CoV-2 neutralization by intravenous immunoglobulins [e-pub ahead of print]. J Infect Dis. 2021. doi:10.1093\/infdis\/jiab482, Accessed July 6, 2022.","DOI":"10.1093\/infdis\/jiab482"},{"issue":"1","key":"10.1016\/j.anai.2022.06.009_bib0071","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1007\/s40259-021-00511-9","article-title":"SARS-CoV-2 neutralization in convalescent plasma and commercial lots of plasma-derived immunoglobulin","volume":"36","author":"Volk","year":"2022","journal-title":"BioDrugs"},{"issue":"6","key":"10.1016\/j.anai.2022.06.009_bib0072","doi-asserted-by":"crossref","first-page":"1958","DOI":"10.1016\/j.jaci.2022.03.026","article-title":"The arrival of SARS-CoV-2-neutralizing antibodies in a currently available commercial immunoglobulin","volume":"149","author":"Miller","year":"2022","journal-title":"J Allergy Clin Immunol"},{"issue":"4","key":"10.1016\/j.anai.2022.06.009_bib0074","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1093\/infdis\/jiab570","article-title":"Monoclonal antibody treatment of breakthrough COVID-19 in fully vaccinated individuals with high-risk comorbidities","volume":"225","author":"Bierle","year":"2022","journal-title":"J Infect Dis"},{"key":"10.1016\/j.anai.2022.06.009_bib0075","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.720205","article-title":"SARS-CoV-2 spike protein-directed monoclonal antibodies may ameliorate COVID-19 complications in APECED patients","volume":"12","author":"Ferr\u00e9","year":"2021","journal-title":"Front Immunol"},{"issue":"13","key":"10.1016\/j.anai.2022.06.009_bib0076","doi-asserted-by":"crossref","first-page":"1236","DOI":"10.1001\/jama.2022.2832","article-title":"Effect of sotrovimab on hospitalization or death among high-risk patients with mild to moderate COVID-19: a randomized clinical trial","volume":"327","author":"Gupta","year":"2022","journal-title":"JAMA"},{"issue":"7","key":"10.1016\/j.anai.2022.06.009_bib0077","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2022.110812","article-title":"LY-CoV1404 (bebtelovimab) potently neutralizes SARS-CoV-2 variants","volume":"39","author":"Westendorf","year":"2022","journal-title":"Cell Rep"},{"key":"10.1016\/j.anai.2022.06.009_bib0079","unstructured":"WHO. Coronavirus (COVID-19) Dashboard; 2022. https:\/\/covid19.who.int. Accessed July 6, 2022."}],"container-title":["Annals of Allergy, Asthma & Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1081120622005294?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1081120622005294?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T13:29:59Z","timestamp":1761053399000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1081120622005294"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11]]},"references-count":87,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2022,11]]}},"alternative-id":["S1081120622005294"],"URL":"https:\/\/doi.org\/10.1016\/j.anai.2022.06.009","relation":{},"ISSN":["1081-1206"],"issn-type":[{"value":"1081-1206","type":"print"}],"subject":[],"published":{"date-parts":[[2022,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Immunizing the imperfect immune system","name":"articletitle","label":"Article Title"},{"value":"Annals of Allergy, Asthma & Immunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.anai.2022.06.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 American College of Allergy, Asthma & Immunology. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}